Adagene Entered into an Exclusive License Agreement with Sanofi to Develop Novel Masked Immuno-Oncology Antibody
Shots:
- Adagene to receive $17.5M up front, ~$2.5B in development, regulatory & commercial milestones along with royalties on sales of approved products. Sanofi gets the rights to advance 2 initial Sanofi’s Abs products, followed by an option for 2 additional candidates
- Adagene will lead the early-stage research activities to develop masked versions of Sanofi candidate Abs by using Adagene’s SAFEbody technology. Sanofi will be responsible for later-stage research, all clinical, product development & commercialization activities
- SAFEbody technology can be used in multiple types of therapeutic modalities, including mAb & bispecific Abs. Additionally, Adagene has 5 Ab-based candidates in IND-enabling studies & ~50 across different stages of discovery
Ref: Globe Newswire | Image: Adagene
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
